Benefits
Osteoarthritis pain reduction
Clinical trials in knee osteoarthritis show meaningful pain reduction and improved function with Theracurmin® at 90-180 mg/day over 8-12 weeks. Effects are modest but reproducible across studies.
Exercise-induced muscle damage recovery
Theracurmin® supplementation reduces markers of exercise-induced muscle damage and accelerates recovery between training sessions. Particularly relevant for athletes and active adults doing high-intensity training.
Cardiovascular endothelial function
Clinical trials in middle-aged and older adults show improvements in flow-mediated dilation (FMD) — a measure of endothelial function — with Theracurmin® supplementation over weeks of use.
Cognitive function in older adults
Trials in older adults show modest cognitive improvements with Theracurmin® supplementation over months of use. Mechanism likely involves the anti-inflammatory and anti-amyloid effects of bioavailable curcumin in the brain.
27x bioavailability advantage
Colloidal nanoparticle technology achieves approximately 27x higher curcumin absorption than standard curcumin powder. Distinguishing technical advantage — explains why effects are seen at 30-180 mg/day rather than the multi-gram doses needed for standard curcumin.
Anti-inflammatory marker reductions
Theracurmin® supplementation reduces CRP, IL-6, and other systemic inflammatory markers in adults with mild chronic inflammation. Effect sizes are modest but consistent with curcumin's known anti-inflammatory mechanism.
Liver health and NAFLD support
Emerging trials in non-alcoholic fatty liver disease show Theracurmin® supplementation may reduce liver enzymes and hepatic fat content over months of use. Promising application area still under investigation.
Mechanism of action
Colloidal nanoparticle dispersion (distinguishing pharmacokinetics)
Curcumin (diferuloylmethane) is dispersed with colloidal nanoparticles via Theravalues' proprietary manufacturing process. The nanoparticle form enables intestinal endothelium penetration that standard crystalline curcumin (poorly water-soluble) cannot achieve. Distinct from phytosome (Meriva), micellar (Longvida), curcumin-piperine (BCM-95), curcumin-fenugreek (CurQfen), and other curcumin formulations.
Increased intestinal endothelium penetrability
Nanoparticle dispersion enables passage through the intestinal endothelium that standard crystalline curcumin cannot achieve due to poor water solubility. The pharmacokinetic basis for the 27× AUC improvement.
NF-κB anti-inflammatory pathway suppression
Curcumin's core anti-inflammatory mechanism via NF-κB pathway suppression. Bioavailable Theracurmin reaches systemic concentrations supporting clinical activity that standard curcumin cannot at comparable doses.
BBB penetration with bioavailable form
The bioavailable nanoparticle form enables blood-brain barrier penetration and central nervous system effects underlying the cognitive benefits. Standard curcumin's poor bioavailability limits CNS exposure.
Amyloid plaque and tau tangle modulation
FDDNP-PET imaging documented changes in brain amyloid plaque and tau tangle deposition, the proposed disease-relevant mechanism underlying the cognitive benefits in non-demented older adults.
Antioxidant via direct ROS scavenging and Nrf2 activation
Direct ROS scavenging plus Nrf2 pathway activation — standard curcumin antioxidant mechanisms now achievable at lower doses due to enhanced bioavailability.
Clinical trials
Clinical evidence on Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues) for the indications and outcomes described.
Clinical population described in trial publication.
Small GW et al. 2014 (Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010). Randomized double-blind placebo-controlled trial in non-demented adults aged 50-90 with mild memory complaints. Theracurmin® 90 mg twice daily (180 mg/day) vs placebo for 18 months. Memory, attention, and mood improvements. FDDNP-PET imaging changes in brain amyloid plaque and tau tangle deposition. UCLA Gary Small lead investigator. The longest cognitive curcumin trial to date.
Theravalues 6-month MCI/AD stabilization trial (n=93).
Clinical population described in trial publication.
Theravalues 6-month MCI/AD stabilization trial (n=93). Non-treated decline vs Theracurmin-treated stabilization in MoCA, ADL, and MMSE. Industry-sponsored — supports cognitive findings in a higher-impairment population.
UCLA-sponsored Phase 2 12-month cognitive trial using Theracurmin Super TS-P1 75 mg/day.
Clinical population described in trial publication.
UCLA-sponsored Phase 2 12-month cognitive trial using Theracurmin Super TS-P1 75 mg/day. Currently in not-yet-recruiting status. Ongoing academic research interest beyond the manufacturer.